April 21st 2024
During a Case-Based Roundtable® event, Raajit K. Rampal, MD, PhD, discussed the correlation between spleen volume responses and survival outcomes for patients with myelofibrosis in the second article of a 2-part series.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Ruxolitinib Extended-Release Could Mitigate Risk/Increase Compliance for Patients With MPNs
March 24th 2023In an interview with Targeted Oncology, Aaron T. Gerds, MD, MS, provided an in-depth discussion on the complete response letter issued to ruxolitinib extended-release, and why continued evaluation of the agent could be beneficial for patients with MPNs.
Read More
FDA Issues Complete Response Letter to Ruxolitinib XR Tablets for MPNs
March 24th 2023The FDA noted that additional requirements are needed prior to the approval of ruxolitinib extended-release for patients with myelofibrosis, polycythemia vera, and graft-versus-host disease, in a complete response letter.
Read More
Abbas Assesses the Use of Allogenic Transplant In MPNs
March 23rd 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Jonathan Abbas, MD, discussed with his fellow clinicians the use of allogeneic hematopoietic stem cell transplant in patients with myeloproliferative neoplasms and how ruxolitinib fits into their care.
Read More
Accelerated Dosing of Ropeginterferon Alfa-2b May Improve Responses in PV
February 6th 2023The dose and titration of ropeginterferon alfa-2b is safe and effective for patients with polycythemia vera. However, additional studies are needed to provide rationale for an amended, higher initial dosage, and rapid titration.
Read More
Roundtable Discussion: Komrokji Evaluates Pathology, Risk Assessment, and Therapy for Myelofibrosis
January 14th 2023During a Targeted Oncology case-based roundtable event, Rami Komrokji, MD, discussed with participants their approach toward assessing and treating a patient with symptoms possibly indicating primary myelofibrosis.
Read More
Ruxolitinib’s Role for Symptoms and Survival Benefit in Myelofibrosis
January 4th 2023During a Targeted Oncology case-based roundtable event, Rami Komrokji, MD, discussed data supporting the use of ruxolitinib and what role it may play in improving long-term outcomes for patients with myelofibrosis. This is the second of 2 articles based on this event.
Read More